← Leaderboards
Estelle Leclerc
North Dakota State University
$958,085
Attributed
$958,085
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $232.7K · FY2011–19$250K$187.5K$125K$62.5K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$958,085 · 2
By mechanism
P20$840,415 · 1
R03$117,670 · 1
Top collaborators
No co-investigators on record.
Most similar at North Dakota State University
Same institution · by research overlap
- Sanku Mallik$9,178,235
- Kausik Sarkar$2,016,545
- Buddhadev Layek$884,621
- Mohiuddin Quadir$81,164
Others in their field
Top investigators on “Affinity”
- Dennis R. Burton · Scripps Research Institute$64,397,776
- James E Crowe · Vanderbilt University Medical Center$53,471,415
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$45,445,140
- Timothy A Springer · Boston Children'S Hospital$41,593,445
- Misty Ward Stevens · Intervexion Therapeutics, Llc$38,187,594
- Rafi Ahmed · Emory University$36,776,987
Research focus
AffinityFlow CytometryCell LineEnzyme-Linked Immunosorbent AssayMonoclonal AntibodiesLigandsFc ReceptorIn VitroMediatingPropertyPeptidesAntibodiesCell Surface ReceptorsApoptosisReceptorImmunoglobulin GAdvanced Glycosylation End ProductsAnticancer ResearchDiagnosticCancerousAnimalsDrug Delivery SystemsChemokineCenters Of Research Excellence
Grant awards (6)
Development of Monoclonal Antibodies to Inhibit RAGE Activation in Pancreatic Cancer tumors$202,810
P20 · FY2019 · GM · contact PI
Development of Monoclonal Antibodies to Inhibit RAGE Activation in Pancreatic Cancer tumors$192,133
P20 · FY2018 · GM · contact PI
Development of Monoclonal Antibodies to Inhibit RAGE Activation in Pancreatic Cancer tumors$212,747
P20 · FY2017 · GM · contact PI
Development of Monoclonal Antibodies to Inhibit RAGE Activation in Pancreatic Cancer tumors$232,725
P20 · FY2016 · GM · contact PI
Targeting RAGE/Abeta interaction with single chain monoclonal antibodies$58,835
R03 · FY2012 · AG · contact PI
Targeting RAGE/Abeta interaction with single chain monoclonal antibodies$58,835
R03 · FY2011 · AG · contact PI